Actively Recruiting
Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
Led by Icahn School of Medicine at Mount Sinai · Updated on 2025-04-23
102
Participants Needed
1
Research Sites
64 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Topical timolol, a β2-Adrenergic receptor (B2AR) antagonist, has demonstrated promise in wound healing over the past several years. The majority of the literature has evaluated the use of topical timolol to shorten wound healing time in chronic wounds of non-surgical etiologies. To date, there are no prospective randomized clinical trials evaluating the role of topical timolol for shortening wound healing time in acute open surgical wounds. Therefore, the purpose of this study is to determine whether or not topical timolol solution decreases time to wound healing in patients with defects after Mohs Micrographic Surgery (MMS) that cannot be closed with sutures and are left to heal by second intent. The research team also will look to determine if there is a difference in cosmesis of wounds treated with topical timolol compared to those treated with the standard of care. The present study will primarily focus on wounds in the distal lower extremity as these are most commonly left to heal by secondary intent
CONDITIONS
Official Title
Topical 0.5% Timolol Solution for Healing Lower Extremity Wounds
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be scheduled to undergo Mohs Micrographic Surgery for skin cancer at the specified location
- Meet Mohs surgery appropriate use criteria
- Have an open surgical wound between 0.5 cm and 4 cm in size
- Be 18 years of age or older
- Be English-speaking
- Provide signed and dated informed consent
- Willing to comply with all study procedures
You will not qualify if you...
- Under 18 years of age
- Open surgical wound larger than 4 cm
- Tumor clearance not achievable with Mohs surgery
- Pregnant or breastfeeding women
- Taking oral beta-blockers (e.g., timolol, metoprolol, carvedilol, propranolol, atenolol)
- Taking clonidine, digoxin, methyldopa, quinidine, fluoxetine, paroxetine, or bupropion
- Taking a calcium channel blocker with pre-existing heart failure
- Pre-existing hypotension
- Diagnosed with sinus bradycardia
- Diagnosed with second or third degree atrioventricular block
- Congestive heart failure
- Severe asthma
- Chronic obstructive pulmonary disease
- Known allergy or sensitivity to 0.5% timolol solution
- Wound where primary closure is possible and desired
- Defect size less than 0.5 cm
- Prior sensitivity or allergy to timolol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Mount Sinai
New York, New York, United States, 10028
Actively Recruiting
Research Team
J
Jesse Lewin, MD
CONTACT
J
Jaclyn Himeles, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here